La société de recherche Bioarctic a reçu un avis du Comité des médicaments orphelins de l'Agence européenne des médicaments ...

La société de recherche Bioarctic annonce une augmentation de son chiffre d'affaires au premier trimestre par rapport à la ...

Get Instant Summarized Text (Gist) Recent advances in PET tracers enable in vivo visualization of α-synuclein aggregates, a hallmark of synucleinopathies such as Parkinson’s disease, multiple ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease (PD), ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

In the last three months, 7 analysts have published ratings on Prothena Corp PRTA +5.63% Get Free Report , offering a diverse ...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...